• Dr Reddy's Laboratories Ltd RDY.N reported quarterly adjusted earnings of ₹16.94​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of ₹16.56. The mean expectation of six analysts for the quarter was for earnings of ₹16.66 per share. Wall Street expected results to range from ₹14.30 to ₹19.10 per share.

• Revenue rose 15.8% to ₹83.81 billion from a year ago; analysts expected ₹81.47 billion.

• Dr Reddy's Laboratories Ltd's reported EPS for the quarter was ₹16.94​.

• The company reported quarterly net income of ₹14.14 billion.

• Dr Reddy's Laboratories Ltd shares had fallen by 4.4% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 6.6% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Dr Reddy's Laboratories Ltd is $17.00

This summary was machine generated from LSEG data January 23 at 06:05 p.m. UTC. ​All figures in Indian rupees unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)